683 Capital Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

683 Capital Management’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-481,190	Closed	-$4.87M	–	265
2023 Q1	$4.87M	Hold	481,190	–	–	0.36%	73
2022 Q4	$4.79M	Hold	481,190	–	–	0.41%	63
2022 Q3	$4.69M	Sell	481,190 -18,810	-4%	-$184K	0.36%	67
2022 Q2	$4.86M	Hold	500,000	–	–	0.34%	73
2022 Q1	$4.85M	Hold	500,000	–	–	0.26%	81
2021 Q4	$4.84M	Hold	500,000	–	–	0.18%	91
2021 Q3	$4.84M	Buy	+500,000	New	+$4.88M	0.19%	86

Other funds holding NKGN

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

SFM

Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

683 Capital Management's NKGN Position: Q2 2023 in Review

683 Capital Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2023, closing a stake of 481,190 shares — an estimated $4.87M sold.

683 Capital Management first reported a position in NKGN in Q3 2021 and held it in 7 quarters. The position peaked at $4.87M in Q1 2023. 25 funds tracked by Wall St. Rank hold NKGN as of Q2 2023.

683 Capital Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
683 Capital Management sold 481,190 NKGen Biotech, Inc. Common Stock shares in Q2 2023, an estimated $4.87M.
683 Capital Management first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
683 Capital Management's NKGen Biotech, Inc. Common Stock position peaked at $4.87M in Q1 2023.
25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.